TY - JOUR
T1 - Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
AU - Quintas-Cardama, Alfonso
AU - Kantarjian, Hagop
AU - O'Brien, Susan
AU - Jabbour, Elias
AU - Giles, Francis
AU - Ravandi, Farhad
AU - Faderl, Stefan
AU - Pierce, Sherry
AU - Shan, Jenny
AU - Verstovsek, Srdan
AU - Cortes, Jorge
PY - 2006/10/1
Y1 - 2006/10/1
N2 - BACKGROUND. Topoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML. METHODS. Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m2 orally daily 5 days a week, every 4 to 6 weeks. RESULTS. Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%. The response rate was similar in MDS and CMML. Severe (Grade 3-4) side effects included nausea and vomiting (7%), diarrhea (18%), other gastrointestinal toxicities (5%), and genitourinary toricities (12%). CONCLUSIONS. 9-NC is active in MDS and CMML. The paucity of available therapies in CMML makes 9-NC a good candidate for further studies as a single agent, or in combination with decitabine, 5-azacitidine or cytarabine.
AB - BACKGROUND. Topoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML. METHODS. Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m2 orally daily 5 days a week, every 4 to 6 weeks. RESULTS. Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%. The response rate was similar in MDS and CMML. Severe (Grade 3-4) side effects included nausea and vomiting (7%), diarrhea (18%), other gastrointestinal toxicities (5%), and genitourinary toricities (12%). CONCLUSIONS. 9-NC is active in MDS and CMML. The paucity of available therapies in CMML makes 9-NC a good candidate for further studies as a single agent, or in combination with decitabine, 5-azacitidine or cytarabine.
KW - 9-nitrocamptothecin
KW - Chronic myelomonocytic leukemia
KW - Myelodysplastic syndrome
UR - http://www.scopus.com/inward/record.url?scp=33749633145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749633145&partnerID=8YFLogxK
U2 - 10.1002/cncr.22186
DO - 10.1002/cncr.22186
M3 - Article
C2 - 16955510
AN - SCOPUS:33749633145
SN - 0008-543X
VL - 107
SP - 1525
EP - 1529
JO - Cancer
JF - Cancer
IS - 7
ER -